-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Patients with severe 2019 coronavirus disease (Covid-19) develop inflammatory disorders that increase the risk of adverse prognosis.
researchers recently examined the treatment of patients with neocytic pneumonia by Janus kinase inhibitor Barrettinib.
the study was a randomized, double-blind, placebo-controlled study that examined the efficacy of Barrettinib and Redsiway in hospital patients with neocytosis.
patients were randomly treated with barrettinib (no more than 14 days) or a placebo on the basis of Redsiway (no more than 10 days of treatment).
end of the study was recovery time, and the secondary endpoint was the clinical state of the patient after 15 days of treatment.
1,033 patients were involved in the study, including 515 in the Barrettinib group and 518 in the placebo group.
recovery time was 7 days in the Bariteni group and 8 days in the control group (recovery rate 1.16).
15-day improvement in clinical status in the Barentinib group was 30% higher than in the placebo group (OR-1.3).
for patients who received high-flow oxygen or noninvasive breath therapy at baseline, the average recovery time in the Barrettinib group was 10 days, while in the placebo group it was 18 days (recovery rate 1.51).
28-day mortality rate was 5.1 per cent in the Bariteni group and 7.8 per cent in the control group (risk of death ratio 0.65).
rates of serious adverse events (16 vs 21 per cent) and new infections (5.9 vs 11.2 per cent) were lower in the Bariteni group.
study found that Barrettinib combined with Redsywe to shorten the recovery time of patients hospitalized with neocytic pneumonia and improve clinical conditions, especially in patients treated with high flow of oxygen or non-invasive breathing.
。